Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia

키워드

참고문헌 (70)

1. Baldessarini, R. J., "Schizophrenia", N. Engl. J. Med., 297, pp.988~995 (1977)
2. Nasrallah, H. A., "The Neurology of schizophrenia" (1985), Elsevier Science Publishers
3. Tamminga, C. A., "Advances in neuropsychiatry and psychopharmacology: schizophrenia research" (1991), Raven Press
4. Kandel, E. R., "Disorders of thought and volition: Schizophrenia. in: Principles of neural science", pp.1188~1208, Elsevier
5. Weinberger, D. R., "Implications of normal brain development for the pathogenesis of schizophrenia", Arch. Gen. Psychiatry, 44, pp.660~669 (1987)
6. Meltzer, H. Y., "Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia", Psychopharmacology, 99, pp.S18~S27 (1989)
7. Davis, K., "Dopamine in schizophrenia: a review and reconceptualization", Am. J. Psychiatry, 148, pp.1474~1486 (1991)
8. Goff, D. C., "The emerging role of glutamate in the pathophysiology and treatment of schizophrenia", Am. J. Psychiatry, 158, pp.1367~1377 (2001)
9. Creese. I., "Dopamine receptor binding predicts clinical and pharmacological potencies of antischizohrenic drugs", Science, 192, pp.481~483 (1976)
10. Angrist, B. M., "The phenomenology of experimentally induced amphetamine psychosispreliminary observations", Biol. Psychiatry, 2, pp.95~107 (1970)
11. Lieberman, J. A., "Provocative tests with psychostimulant drugs in schizophrenia", Psychopharmacology, 91, pp.415~433 (1987)
12. Seeman, P., "Brain dopamine receptors", Pharmacol. Rev., 32, pp.229~313 (1980)
13. Seeman, P., "Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4", Neuropsychopharmacol., 7, pp.261~285 (1992)
14. Wong, D. F., "Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics", Science, 234, pp.1558~1563 (1986)
15. Farde, L., "D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with (11C) raclopride", Arch. Gen. Psychiatry., 47, pp.213~219 (1990)
16. Hietala, J., "Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography", Arch. Gen. Psychiatry, 51, pp.116~123 (1994)
17. Tarazi, F. I., "Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment", Neuroscience, 78, pp.985~996 (1997)
18. Tarazi, F. I., "Longterm effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment", J. Pharmacol. Exp. Ther., 297, pp.711~717 (2001)
19. Moran-Gates, T., "Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects", Synapse, 59, pp.92~100 (2006)
20. Moran-Gates, T., "Effects of risperidone on dopamine receptor subtypes in developing rat brain", Eur. Neuropsychopharmacol., 17, pp.448~555 (2007)
21. Tsai, G., "Glutamatergic mechanisms in schizophrenia", Ann. Rev. Pharmacol. Toxicol., 42, pp.165~179 (2002)
22. Javitt, D. C., "Recent advances in the phencyclidine model of schizophrenia", Am. J. Psychiatry, 148, pp.1301~1308 (1991)
23. Moller, P., "The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior", Schizophr. Bull., 26, pp.217~232 (2000)
24. Silver, H., "Working memory deficit as a core neuropsychological dysfunction in schizophrenia", Am. J. Psychiatry, 160, pp.1809~1816 (2003)
25. Mohn, A. R., "Mice with reduced NMDA receptor expression display behaviors related to schizophrenia", Cell, 98, pp.427~436 (1999)
26. Meador-Woodruff, J. H., "Glutamate receptor expression in schizophrenic brain", Brain. Res. Rev., 31, pp.288~294 (2000)
27. Meshul, C. K., "Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses", J. Neurochem., 67, pp.1965~1973 (1996)
28. Tarazi, F. I., "Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics", Psychopharmacology, 128, pp.371~379 (1996)
29. MK801-binding sites in the rat brain: a side-preference action in cortical areas, "Brain Res.", 1997, 216~218
30. McCoy, L., "Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression", Synapse, 28, pp.195~207 (1998)
31. Spurney, C. F., "Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats", Synapse, 34, pp.266~276 (1999)
32. Fitzgerald, L. W., "Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs", J. Neurosci., 15, pp.2453~2461 (1995)
33. Riva, M. A., "Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs", Mol. Brain Res., 50, pp.136~142 (1997)
34. Healy, D. J., "Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum", Mol. Brain Res., 47, pp.331~338 (1997)
35. Thöny, B., "Tetrahydrobiopterin biosynthesis, regeneration and functions", Biochem. J., 347(1), pp.1~16 (2000)
36. Blau, N., "Disorders of tetrahydrobiopterin and related biogenic amines; in The metabolic and molecular bases of inherited disease", pp.1725~1776 (2001), McGraw-Hill
37. Park, Y. S., "Human carbonyl and aldose reductases: new catalytic functions in tetrahydrobiopterin biosynthesis", Biochem. Biophys. Res. Commun., 175, pp.738~744 (1991)
38. Kaufman, S., "The structure of the phenylalaninehydroxylation cofactor", Proc. Natl. Acad. Sci. U.S.A., 통권 : 50, pp.1085~1093 (1963)
39. Levitt, M., "Elucidation of the rate-limiting step in norepinephrine biosynthesis in perfused guinea-pig heart", J. Pharmacol. Exp. Ther., 148, pp.1~8 (1965)
40. Hosoda, S., "Studies in histochemistry. LXXIX. Properties of tryptophan hydroxylase from neoplastic murine mast cells", J. Biol. Chem., 241, pp.192~196 (1966)
41. Kwon, N. S., "Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages", J. Biol. Chem., 264, pp.20496~20501 (1989)
42. Tayeh, M. A., "Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor", J. Biol. Chem., 264, pp.19654~19658 (1989)
43. Sumi-Ichinose, C., "Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvoyltetrahydropterin synthase knockout mice", J. Biol. Chem., 276, pp.41150~41160 (2001)
44. Yang, S., "A murine model for human sepiapterin-reductase deficiency", Am. J. Hum. Genet., 78, pp.575~587 (2006)
45. Kuhn, D. M., "Tetrahydrobiopterin prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide", Mol. Pharmacol., 64, pp.946~953 (2003)
46. Satoh, M., "NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy", Am. J. Physiol. Renal. Physiol., 288, pp.F1144~F1152 (2005)
47. Satoh, M., "Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy", Nephrol. Dial. Transplant., 23, pp.3806~3813 (2008)
48. Snyder, S. H., "Novel neurotransmitters and their neuropsychiatric relevance", Am. J. Psychiatry, 157, pp.1738~1751 (2000)
49. Brenman, J. E., "Synaptic signaling by nitric oxide", Curr. Opin. Neurobiol., 7, pp.374~378 (1997)
50. Akyol, O., "Nitric oxide as a physiopathological factor in neuropsychiatric disorders", In Vivo, 18, pp.377~390 (2004)
51. Kiss, J. P., "Role of nitric oxide in the regulation of monoaminergic neurotransmission", Brain Res. Bull., 52, pp.459~466 (2000)
52. Mataga, N., "6R-tetrahydrobiopterin perfusion enhances dopamine, serotonin, and glutamate outputs in dialysate from rat striatum and frontal cortex", Brain Res., 551, pp.64~71 (1991)
53. Koshimura, K., "Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin", J. Neurochem., 54, pp.1391~1397 (1990)
54. Liang, L. P., "The regulation of dopamine release from striatum slices by tetrahydrobiopterin and L-arginine-derived nitric oxide", Brain Res., 800, pp.181~186 (1998)
55. Wolf, W. A., "Effect of tetrahydrobiopterin on serotonin synthesis, release, and metabolism in superfused hippocampal slices", J. Neurochem., 57, pp.1191~1197 (1991)
56. Fiege, B., "Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration", Mol. Genet. Metab., 81, pp.45~51 (2004)
57. Garbutt, J. C., "Cerebrospinal fluid hydroxylase cofactor in schizophrenia", Psychiatry Res., 6, pp.145~151 (1982)
58. Duch, D. S., "Urinary excretion of biopterin and neopterin in psychiatric disorders", Psychiatry. Res., 11, pp.83~89 (1984)
59. Leeming, R. J., "Biopterin derivatives in human body fluids and tissues", J. Clin. Pathol., 29, pp.444~451 (1976)
60. Richardson, M. A., "Evidence for a tetrahydrobiopterin deficit in schizophrenia", Neuropsychobiology, 52, pp.190~201 (2005)
61. Richardson, M. A., "Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder", Neurochem. Res., 32, pp.107~113 (2007)
62. Bjerkenstedt, L., "Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls", Br. J. Psychiatry, 147, pp.276~282 (1985)
63. Lindström, L. H., "Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history", Psychiatry. Res., 14, pp.265~273 (1985)
64. Gattaz, W. F., "CSF monoamine metabolites in schizophrenic patients", Acta. Psychiatr. Scand., 66, pp.350~360 (1982)
65. Potkin, S. G., "Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles", Am. J. Psychiatry, 140, pp.21~25 (1983)
66. Eells, J. B., "Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice", Brain Res. Bull., 70, pp.186~195 (2006)
67. Gil, M., "Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo", J. Neurochem., 101, pp.142~150 (2007)
68. Xing, G., "Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders", Schizophr. Res., 84, pp.36~56 (2006)
69. Hitri, A., "Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance", Clin. Neuropharmacol., 17, pp.1~22 (1994)
70. Giros, B., "Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter", Nature, 379, pp.606~612 (1996)

관련 논문AI추천